Ain-Shams Journal of Anesthesiology

Table 2 Outcome

From: Impact of Ivabradine on renal function in septic patient with early renal impairment

	Group C (n=25)	Group I (n=25)	Tests
	Mean±SD	Mean±SD	t/X²	P-value
Heart rate (beat/min.)
T0	98.20±7.21	96.84±3.33	0.856	0.396
T1	93.32±5.78	87.04±3.23	4.742	<0.001**
T2	86.36±5.82	78.36±3.03	6.095	<0.001**
T3	84.64±5.03	68.8±3.34	13.111	<0.001**
Urine output (ml/24 hrs.)
T0	834.44±88.50	829.60±105.17	0.176	0.861
T1	1102.48±165.75	1090.40±179.53	0.247	0.806
T2	1583.56±169.26	1684.60±169.40	2.110	0.040*
T3	1838.44±131.88	2141.96±210.83	6.103	<0.001**
cystatin c (mg/l)
T0	1.71±0.16	1.79±0.17	1.571	0.123
T1	1.57±0.14	1.42±0.15	3.653	0.002*
T2	1.36±0.12	1.14±0.13	6.421	<0.001**
T3	1.21±0.15	0.98±.12	5.615	<0.001**
eGFR (ml/min/1.73m²)
T0	44.68±3.67	44.24±3.38	0.441	0.661
T1	70.24±4.59	73.76±4.44	2.758	0.008*
T2	79.20±4.07	82.96±5.68	2.689	0.010*
T3	96.52±6.36	103.32±6.96	3.606	<0.001**
Number need HD	4(16%)	2(8%)	0.758	0.384
Vasopressor (μg/kg/min.)
T0	0.41±0.06	0.39±0.06	0.659	0.513
T1	0.36±0.03	0.35±0.03	1.161	0.252
T2	0.33±0.07	0.27±0.06	3.272	0.002*
T3	0.16±0.03	0.14±0.03	2.240	0.030*
Length of stay	12(48%)	9(36%)	0.739	0.390
Mortality	2(8%)	2(8%)	0.000	1.000

Group (C): received conventional treatment sepsis and placebo tablet, Group (I): received conventional treatment sepsis and Ivardrabine tablet, HD: hemodialysis, eGFR C :estimated glomerular filtration rate based on cystatin C, T0: baseline value, T1: day 1 after beginning of the study. T2: day 1 after beginning of the study T3: day 1 after beginning of the study

Back to article page